Alterations of protein 4.1 family members in ependymomas: A study of 84 cases

Modern Pathology

Volumn 18, Issue 7, 2005, Pages 991-997

  Rajaram, Veena ^a   Gutmann, David H ^a   Prasad, Srinivas K ^a   Mansur, David B ^a   Perry, Arie ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ependymoma; NF2; Pediatric; Prognosis; Protein 4.1; Tumor genetics

Indexed keywords

ANTIBODY; ERYTHROCYTE BAND 4.1 PROTEIN; PROTEIN 4.1B; PROTEIN 4.1G; PROTEIN 4.1R; PROTEIN NF2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CHILD; CONTROLLED STUDY; EPENDYMOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE PROBE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD TUMOR; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BLOOD PROTEINS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOSKELETAL PROTEINS; EPENDYMOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEUROFIBROMIN 2; SPINAL CORD NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 23044505436     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800390     Document Type: Article

References (28)

1. Wiestler OD, Schiffer D, Coons SW, et al. Ependymoma. In: Kleihues P, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. IARC Press: Lyon, 2000, pp 72-82.
2. Schiffer D, Chio A, Giordana MT, et al. Histologic prognostic factors in ependymoma. Childs Nerv Syst 1991;7:177-182.
3. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995;37:655-667.
4. Ernestus R-I, Schroder R, Stutzer H, et al. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 1997;11:421-428.
5. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998;88: 695-703.
6. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg 2000;93:605-613.
7. Mansur DB, Michalski JM, Wahab SH, et al. Long-term results of surgery and post-operative radiation therapy in the curative management of intracranial ependymoma. Int J Radiat Oncol Biol Phys 2002;54:204-205.
8. Rajaram V, Leuthardt EC, Singh PK, et al. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol 2004;17:9-14.
9. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chrom Cancer 1992;5:348-356.
10. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999;113:1-8.
11. Zheng P, Pang JC, Hui AB, et al. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet 2000;122:18-25.
12. Rubio M-P, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994;54:45-47.
13. Gutmann DH, Giordano MJ, Fishback BS, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49: 267-270.
14. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-632.
15. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001;91:803-808.
16. Singh PK, Gutmann DH, Fuller CE, et al. Differential involvement of protein 4.1 family members DAL1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 2002;15:526-531.
17. Gutmann DH. The neurofibromatoses: when less is more. Hum Mol Genet 2001;10:747-755.
18. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2001;92:305-316.
19. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999;24:230-237.
20. Tong CY-K, Zheng P-P, Pang JC-S, et al. Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers. J Neurosurg 2001;95:9-14.
21. Scheil S, Bruderlein S, Eicker M, et al. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 2001;11:133-143.
22. Parra M, Gascard P, Walensky LD, et al. Cloning and characterization of 4.1G (EPB41L2), a new member of the skeletal protein 4.1 (EPB41) gene family. Genomics 1998;49:298-306.
23. Scott C, Keating L, Bellamy M, et al. Protein 4.1 in forebrain postsynaptic density preparations. Enrichment of 4.1 gene products and detection of 4.1R binding proteins. Eur J Biochem 2001;268:1084-1094.
24. Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningioma. Hum Mol Genet 2000;9:1495-1500.
25. Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-879.
26. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: A clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001;60: 994-1003.
27. Robb VA, Li W, Gascard P, et al. Identification of a third protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003;13: 191-202.
28. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003;163:1721-1727.